Carcinoid heart disease (CHD) complicates approximately 25% of patients with a carcinoid tumor and carcinoid syndrome and leads to heart valve degeneration with mixed-stenotic and regurgitation pathology and consequent heart failure (HF) leading to significant morbidity and mortality. Cardiac surgery in symptomatic, severe CHD leads to significantly better functional capacity and prolonged survival when compared to medical treatment alone. Recent studies have shown improvement in postoperative outcomes of patients undergoing surgery for CHD over the last decades. The trend for early diagnosis and application of surgery prior to the manifestation of HF symptoms, which tended to develop during the previous years, does not seem justifiable based on the findings of recent studies. Therefore, the optimal timing of intervention in CHD and the type of valve that should preferably be used remain issues of controversy. This review comprehensively examines the existing literature on the treatment options for patients with CHD, with a special focus on short- and long-term survival after cardiac surgery, and discusses the selection of the exact patient profile and intervention timing that are more likely to optimize the benefit-to-risk ratio for surgical intervention.

Keywords:
Carcinoid syndrome, Valvular disease, Cardiac surgery
1.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
2.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after ‘carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
3.
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL: NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-734.
4.
Maxwell JE, O'Dorisio TM, Howe JR: Biochemical diagnosis and preoperative imaging of gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2016;25:171-194.
5.
Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G: Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013;168:185-193.
6.
Horton KM, Kamel I, Hofmann L, Fishman EK: Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 2004;182:559-567.
7.
Patel C, Mathur M, Escarcega RO, Bove AA: Carcinoid heart disease: current understanding and future directions. Am Heart J 2014;167:789-795.
8.
Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196.
9.
Moyssakis IE, Rallidis LS, Guida GF, Nihoyannopoulos PI: Incidence and evolution of carcinoid syndrome in the heart. J Heart Valve Dis 1997;6:625-630.
10.
Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK: Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410-416.
11.
Bernheim AM, Connolly HM, Rubin J, Møller JE, Scott CG, Nagorney DM, Pellikka PA: Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc 2008;83:143-150.
12.
Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I, Gross DJ: Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008;159:475-482.
13.
Kaltsas G, Grossman AB: The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. Clin Endocrinol (Oxf) 2015;83:759-761.
14.
Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis GZ, Öberg K, Kaltsas G, Tsolakis AV: Expression of somatostatin receptors 1-5 and dopamine receptor 2 in lung carcinoids: implications for a therapeutic role. Neuroendocrinology 2015;101:211-222.
15.
Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J: Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011;107:1221-1226.
16.
Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol 2013;72:387-395.
17.
Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K: Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015;9:5075-5086.
18.
Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A: Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 2014;21:705-714.
19.
Lafaras CT, Mandala EM, Platogiannis DN, Saratzis AN, Barbetakis NG, Paraskevopoulos PP, Ilonidis GC, Bischiniotis TS: Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study. Onkologie 2010;33:300-304.
20.
Askew JW, Connolly HM: Carcinoid valve disease. Curr Treat Options Cardiovasc Med 2013;15:544-555.
21.
Obel O, Coltart DJ, Signy M: Balloon pulmonary valvuloplasty in carcinoid syndrome. Heart 2000;84:E13.
22.
Carrilho-Ferreira P, Silva D, Almeida AG, Infante de Oliveira E, Ferreira C, Miranda L, Rosa R, Canas da Silva P, Bicha Castelo H, Nunes Diogo A: Carcinoid heart disease: outcome after balloon pulmonary valvuloplasty. Can J Cardiol 2013;29:751.e7-e9.
23.
Skhiri M, Hunt SA, Denault AY, Haddad F: Evidence-based management of right heart failure: a systematic review of an empiric field. Rev Esp Cardiol 2010;63:451-471.
24.
Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, McLaughlin V, Francis G: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792.
25.
Eshtehardi P, Mojadidi MK, Khosraviani K, Pamerla M, Zolty R: Does spironolactone have a survival benefit in patients with isolated right ventricular failure secondary to severe pulmonary hypertension? (abstract). J Am Coll Cardiol 2014;63(12 S):549.
26.
Connolly HM, Schaff HV, Mullany CJ, Abel MD, Pellikka PA: Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation 2002;106:I51-I56.
27.
Lillegard JB, Fisher JE, Mckenzie TJ, Que FG, Farnell MB, Kendrick ML, Donohue JH, Reid-Lombardo K, Schaff HV, Connolly HM, Nagorney DM: Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? J Am Coll Surg 2011;213:130-136; discussion 136-138.
28.
Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R, Grossman A; Barcelona Consensus Conference participants: ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135-156.
29.
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society: Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013;42:557-577.
30.
Dobson R, Valle JW, Burgess MI, Poston GJ, Cuthbertson DJ: Variation in cardiac screening and management of carcinoid heart disease in the UK and Republic of Ireland. Clin Oncol (R Coll Radiol) 2015;27:741-746.
31.
Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK: Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410-416.
32.
Møller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM: Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005;112:3320-3327.
33.
Edwards NC, Yuan M, Nolan O, Pawade TA, Oelofse T, Singh H, Mehrzad H, Zia Z, Geh JI, Palmer DH, May CJ, Ayuk J, Shah T, Rooney SJ, Steeds RP: Effect of valvular surgery in carcinoid heart disease: an observational cohort study. J Clin Endocrinol Metab 2016;101:183-190.
34.
Robiolio PA, Rigolin VH, Harrison JK, Lowe JE, Moore JO, Bashore TM, Feldman JM: Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995;75:485-488.
35.
Weingarten TN, Abel MD, Connolly HM, Schroeder DR, Schaff HV: Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg 2007;105:1192-1199.
36.
Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, Inda JJ, Luis SA, Nishimura RA, Pellikka PA: Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;66:2189-2196.
37.
Schoen FJ, Hausner RJ, Howell JF, Beazley HL, Titus JL: Porcine heterograft valve replacement in carcinoid heart disease. J Thorac Cardiovasc Surg 1981;81:100-105.
38.
Lundin L, Hansson HE, Landelius J, Oberg K: Surgical treatment of carcinoid heart disease. J Thorac Cardiovasc Surg 1990;100:552-561.
39.
Knott-Craig CJ, Schaff HV, Mullany CJ, Kvols LK, Moertel CG, Edwards WD, Danielson GK: Carcinoid disease of the heart: surgical management of ten patients. J Thorac Cardiovasc Surg 1992;104:475-481.
40.
Castillo JG, Filsoufi F, Rahmanian PB, Anyanwu A, Zacks JS, Warner RR, Adams DH: Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol 2008;51:1507-1509.
41.
Arghami A, Connolly HM, Abel MD, Schaff HV: Quadruple valve replacement in patients with carcinoid heart disease. J Thorac Cardiovasc Surg 2010;140:1432-1434.
42.
Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J: Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg 2011;40:168-172.
43.
Mokhles P, van Herwerden LA, de Jong PL, de Herder WW, Siregar S, Constantinescu AA, van Domburg RT, Roos-Hesselink JW: Carcinoid heart disease: outcomes after surgical valve replacement. Eur J Cardiothorac Surg 2012;41:1278-1283.
44.
Claure RE, Drover DD, Haddow GR, Esquivel CO, Angst MS: Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management. Can J Anaesth 2000;47:334-337.
45.
Regner KR, Connolly HM, Schaff HV, Albright RC: Acute renal failure after cardiac surgery for carcinoid heart disease: incidence, risk factors, and prognosis. Am J Kidney Dis 2005;45:826-832.
46.
Ohri SK, Schofield JB, Hodgson H, Oakley CM, Keogh BE: Carcinoid heart disease: early failure of an allograft valve replacement. Ann Thorac Surg 1994;58:1161-1163.
47.
Castillo JG, Filsoufi F, Rahmanian PB, Zacks JS, Warner RR, Adams DH: Early bioprosthetic valve deterioration after carcinoid plaque deposition. Ann Thorac Surg 2009;87:321.
48.
Said SM, Burkhart HM, Schaff HV, Johnson JN, Connolly HM, Dearani JA: When should a mechanical tricuspid valve replacement be considered? J Thorac Cardiovasc Surg 2014;148:603-608.
49.
Komoda S, Komoda T, Pavel ME, Morawietz L, Wiedenmann B, Hetzer R, Lehmkuhl HB: Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg 2011;59:780-785.
50.
Haugaa KH, Bergestuen DS, Sahakyan LG, Skulstad H, Aakhus S, Thiis-Evensen E, Edvardsen T: Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease. J Am Soc Echocardiogr 2011;24:644-650.
51.
Zahid W, Bergestuen D, Haugaa KH, Ueland T, Thiis-Evensen E, Aukrust P, Fosse E, Edvardsen T: Myocardial function by two-dimensional speckle tracking echocardiography and activin A may predict mortality in patients with carcinoid intestinal disease. Cardiology 2015;132:81-90.
52.
Castillo JG, Milla F, Adams DH: Surgical management of carcinoid heart valve disease. Semin Thorac Cardiovasc Surg 2012;24:254-260.
53.
Luis SA, Pellikka PA: Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab 2016;30:149-158.
54.
Kesarwani M, Ports TA, Rao RK, Mahadevan VS: First-in-human transcatheter pulmonic valve implantation through a tricuspid valve bioprosthesis to treat native pulmonary valve regurgitation caused by carcinoid syndrome. JACC Cardiovasc Interv 2015;8:e161-e163.
55.
Khan JN, Doshi SN, Rooney SJ, Bhabra MS, Steeds RP: Transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration in carcinoid heart disease. Eur Heart J Cardiovasc Imaging 2016;17:114.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.